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Acquired differential regulation of caspase-8
in cisplatin-resistant non-small-cell lung cancer
I Paul1, AD Chacko1,4, I Stasik1,4, S Busacca2, N Crawford1, F McCoy1, N McTavish1, B Wilson1, M Barr3, KJ O’Byrne3,
DB Longley1 and DA Fennell*,2
Failure to efficiently induce apoptosis contributes to cisplatin resistance in non-small-cell lung cancer (NSCLC). Although
BCL-2-associated X protein (BAX) and BCL-2 antagonist killer (BAK) are critical regulators of the mitochondrial apoptosis
pathway, their requirement has not been robustly established in relation to cisplatin. Here, we show that cisplatin can efficiently
bypass mitochondrial apoptosis block caused by loss of BAX and BAK, via activation of the extrinsic death receptor pathway in
some model cell lines. Apoptosis resistance following cisplatin can only be observed when both extrinsic and intrinsic pathways
are blocked, consistent with redundancy between mitochondrial and death receptor pathways in cisplatin-induced apoptosis. In
H460 NSCLC cells, caspase-8 cleavage was shown to be induced by cisplatin and is dependent on death receptor 4, death
receptor 5, Fas-associated protein with death domain, acid sphingomyelinase and ceramide synthesis. In contrast, cisplatin-
resistant cells fail to activate caspase-8 via this pathway despite conserving sensitivity to death ligand-driven activation.
Accordingly, caspase-8 activation block acquired during cisplatin resistance, can be bypassed by death receptor agonism.
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Lung cancer is the leading cause of cancer mortality with over
one million new cases diagnosed each year.1 The most
common type is non-small-cell lung cancer (NSCLC), which
accounts for 80% of all primary lung cancer.2 The majority of
patients present with advanced disease, whereby surgical
resection is of no benefit and systemic therapy forms the
mainstay of treatment.3 Platinum-based therapy is the
mainstay of first line therapy but is associated with high
failure with response rates in the region of 20% observed.4,5 In
recent years, our understanding of how to treat NSCLC has
undergone a paradigm shift initiated by the identification of
somatic activating mutations in the epidermal growth factor
receptor (EGFR).6,7 Lethality relies on the efficient induction
of apoptosis involving the BH3-only domain containing
protein, BIM.8–11 Similarly, ELK4-ALK (anaplastic lymphoma
kinase) translocation12 is associated with extreme preclinical
sensitivity to respective ALK kinase inhibition in both
preclinical and clinical settings. Additional molecular sub-
classes with associated somatic gene alterations have been
discovered, predominantly in lung adenocarcinomas and
include mutations of BRAF,13 human epidermal growth factor
receptor 214 and phosphoinositide-3-kinase, catalytic, alpha
polypeptide.15 Despite these advances the majority of
patients still fall outside these subclasses and rely on standard
cisplatin-based treatment.
Induction of apoptosis is important in mediating tumour
response to platinum-based chemotherapy. Defective apop-
tosis underpins drug resistance and is a hallmark of
cancer.16,17 Apoptosis can be initiated through two principle
core signalling pathways, which are death receptor- or
mitochondria-dependent. The mitochondrial apoptotis path-
way is regulated by the multidomain pro-apoptotic B-cell
lymphoma-2 (BCL-2) family proteins, BCL-2-associated X
protein (BAX) and BCL-2 antagonist killer (BAK). These
induce permeabilization of the outer mitochondrial membrane
upstream of effector caspases. Double knockout of these
proteins is sufficient to confer multidrug resistance in mouse
embryonic fibroblasts, however, their requirement for the
action of cisplatin is less well defined.18,19
Altered expression of BAX and BAK has been frequently
reported in NSCLC with BAX expression lost in 34–47% and
BAK expression lost in 42–59% of surgically resected NSCLC
tumours.20–25 Although these studies failed to demonstrate
any prognostic effect of loss of these proteins, analysis was
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carried out for each gene in isolation and the majority of
patients did not receive adjuvant therapy. Given that BAX and
BAK are frequently lost in NSCLC, we hypothesised that loss
of both BAX and BAK in NSCLC could potentially mediate
profound chemoresistance. In contrast, however, our findings
reveal that BAX and BAK are dispensable for cisplatin-
mediated apoptosis in some model systems, where genera-
tion of ceramide can induce apoptosis via caspase-8. More-
over, in cisplatin-resistant NSCLC cells, although both the
intrinsic apoptotic pathway and caspase-8 activation are
impaired in response to cisplatin, sensitivity to death receptor
activation is still conserved.
Results
Silencing BAX and BAK in H460 and H1299 cells results
in mitochondrial apoptosis block. In order to determine if
mitochondrial apoptosis block would confer resistance to
cisplatin-induced apoptosis in NSCLC cells, we generated
H460 and H1299 clones expressing short hairpin RNAs
(shRNAs) simultaneously targeting BAX and BAK. Pairs of
clones with different BAX and BAK targeting sequences were
generated (sh-BAXBAK) and comparisons made with stably
expressing non-targeting (NT) short hairpin RNA (shRNA)
clones (sh-NTNT). BAX and BAK protein expression in H460
clones sh-BAXBAK 1C and 4F was undetectable and in
H1299 clones sh-BAXBAK 1F1A and 2A4B was considerably
reduced as assessed by western blotting (Figure 1a).
We next confirmed that the level of BAX and BAK silencing
in our clones was sufficient to block mitochondrial apoptosis.
All sh-BAXBAK clones showed inhibition of caspase-9
cleavage to the p37 form following 24 h treatment with
staurosporine, versus sh-NTNT controls (Figure 1b). Cas-
pase-3 activation was also significantly attenuated after
staurosporine in the sh-BAXBAK clones of both H460 and
H1299 cells compared with the respective sh-NTNT controls
(Figure 1c). The H460 sh-BAXBAK clones also exhibited
resistance to pro-apoptotic peptides corresponding to the BH3
domain of the pro-apoptotic protein BID (BH3BID) both at
isolated mitochondria and whole-cell level, as we recently
Figure 1 BAXBAK silenced NSCLC cells have mitochondrial apoptosis block. (a) Western blot showing BAX and BAK protein expression in H460 and H1299 sh-BAXBAK
clones compared with corresponding sh-NTNT controls. (b) Western blot for caspase-9 following 24 h treatment with indicated doses of staurosporine in sh-NTNT and sh-
BAXBAK clones from H460 and H1299 cells. (c) Luminescent DEVD-ase assay measuring caspase-3-like activity in sh-NTNT and sh-BAXBAK cells from H460 and H1299
shown relative to untreated control. Data are expressed as mean±S.D. (*Po0.001)
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reported.26 Together these data show that stable knockdown
of BAX and BAK using short hairpin RNA interference in H460
and H1299 cells results in effective suppression of mitochon-
drial apoptotic signalling.
Cisplatin efficiently induces apoptosis in H460 sh-
BAXBAK cells but not H1299 sh-BAXBAK cells. Having
demonstrated mitochondrial apoptosis block in both cell
lines in response to staurosporine (Figures 1b and c) and
R8BID,
26 we wanted to study the effect that this block would
have on cisplatin-induced apoptosis. H460 sh-BAXBAK
cells showed no attenuation in apoptosis after treatment
with cisplatin, as evidenced by sub-G0/G1 fraction
(Figure 2a). In contrast, H1299 sh-BAXBAK clones showed
statistically significant attenuation of apoptosis induction, as
evidenced by sub-G0/G1 fraction, compared with sh-NTNT
control cells (Figure 2b). These results were confirmed by
immunoblot detection of poly (ADP-ribose) polymerase
(PARP) cleavage (Supplementary Figure S1). To under-
stand what could be the reason for this difference in
apoptotic response, we assessed activation of caspase-3.
H460 sh-BAXBAK cells showed no attenuation in caspase-3
activity after cisplatin treatment, whereas a significant
reduction was observed in H1299 sh-BAXBAK clones
(Figure 2c). Together, these data show that cisplatin can
induce apoptosis independent of BAX and BAK in H460
cells, however, in H1299 cells, cisplatin-induced apoptosis
is BAX/BAK-dependent.
Cisplatin induces caspase-8 cleavage in a panel of
NSCLC cell lines and H460 sh-BAXBAK clones, but not
in H1299 cells. It has been shown previously that che-
motherapy treatment has effects on the death receptor
pathway by sensitising a number of different cell types
to TNF receptor-related apoptosis inducing ligand
(TRAIL).27,28 It has also been reported that cisplatin leads
to Fas receptor clustering and activation independent of
ligand binding.29 This led us to hypothesise that cisplatin
induces apoptosis independently of BAX and BAK through
its effects on caspase-8, the initiator caspase of the death
receptor pathway. Accordingly, caspase-8 cleavage in
response to cisplatin was assessed in a panel of NSCLC
lines. Cleavage of procaspase-8 to p41/43-caspase-8
was detected by western blotting in all four cell lines
studied, in a dose-dependent manner, after 24 h exposure
to cisplatin (Figure 3a). To validate these data, caspase-8
activity assays were performed, showing caspase-8 activity
in these cells in response to cisplatin (Supplementary
Figure S8). Together these data suggest that cisplatin-
induced caspase-8 activity is a common feature in NSCLC
cell lines.
Next, we assessed caspase-8 cleavage following cisplatin
treatment in the sh-BAXBAK and sh-NTNT clones as a
possible explanation for the difference observed in caspase-3
activity in sh-BAXBAK cells. In H460 cells, caspase-8 was
cleaved in both sh-NTNT and sh-BAXBAK clones. Caspase-8
cleavage, however, was not detected in any of the H1299
clones (Figure 3b). Again these data were supported by
similar findings using the caspase-8 activity assay
(Supplementary Figure S9).
Caspase-8 silencing rescues H460 sh-BAXBAK cells but
not sh-NTNT control cells from cisplatin-induced apop-
tosis. Cisplatin-induced caspase-8 cleavage in H460 cell
line was sufficient to drive apoptosis independent of BAX and
BAK, contrary to H1299 cells, where caspase-8 cleavage
was not seen after cisplatin treatment, implicating BAXBAK
Figure 2 Cisplatin induces apoptosis in H460 sh-BAXBAK cells but not H1299
sh-BAXBAK cells. (a) Flow cytometry of PI-stained H460 clones after 48 h treatment
with cisplatin. Apoptotic cells are indicated by increase in sub-G0/G1 population. (b)
Flow cytometry of of PI-stained H1299 clones after 48 h treatment with cisplatin.
Apoptotic cells are indicated by increase in sub-G0/G1 population (*Po0.001,
**Po0.01). Data are expressed as mean±S.D. (c) Luminescent DEVD-ase assay
measuring caspase-3-like activity in sh-NTNT and sh-BAXBAK cells from H460 and
H1299 after 24 h treatment with cisplatin, shown relative to untreated controls. Data
are expressed as mean±S.D. (*Po0.001)
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dependence. To confirm whether caspase-8 was required for
apoptosis signalling in the absence of BAXBAK, we silenced
caspase-8 expression in H460 sh-BAXBAK clones using
transient siRNA transfection. TRAIL treatment was included
as a positive control to confirm the level of caspase-8
silencing was sufficient to block death ligand/death receptor-
driven apoptosis. Significant attenuation in cisplatin-induced
apoptosis was noted in both H460 sh-BAXBAK clones
studied (1C and 4F) in the caspase-8-silenced cells
compared with scrambled control siRNA (Figure 4a).
Attenuation in caspase-3 activation was also detected (data
not shown). However, in control sh-NTNT cells silencing of
caspase-8 did not prevent sh-NTNT cells and apoptosis
induction (Figure 4b). These data show that redundancy can
exist between intrinsic and extrinsic apoptosis pathways in
response to cisplatin. In H1299 cells, the death receptor
pathway is dysfunctional as evidenced by their resistance to
rhTRAIL.30 This was associated with reduced procaspase-8,
death receptor 4 (DR4) and death receptor 5 (DR5)
expression as compared with H460 cells (Figure 3b and
Supplementary Figure S2).
To determine if cisplatin-induced caspase-8 cleavage was
dependent on formation of the death inducing signalling
complex (DISC), its components were silenced in H460 sh-
BAXBAK cells and cisplatin-induced caspase-8 cleavage was
assessed (Figure 4c). Silencing of the death receptors, DR4
and DR5 did not affect generation of p41/43-caspase-8, but
resulted in partial attenuation of p18-caspase-8 generation
after cisplatin. This correlated with attenuation in PARP
cleavage. Furthermore, silencing Fas-associated protein with
death domain (FADD) resulted in marked attenuation of p41/
43-caspase-8 and no detectable p18-caspase-8 after 24 h
cisplatin treatment. Again this correlated with attenuation of
PARP cleavage (Figure 4c). Additionally, caspase-3/7 activa-
tion was reduced following silencing of either one of the DISC
components (Supplementary Figure S3). Similar results were
also observed in both H460 sh-BAXBAK 1C and sh-
BAXBAK4F clones (not shown). In contrast, Fas silencing
had no effect on cisplatin-induced apoptosis (Supplementary
Figure S4).
Cisplatin-induced procaspase-8 cleavage is acid sphin-
gomyelinase (ASM)-dependent. It has been shown pre-
viously that cisplatin can induce ceramide generation.31 We
therefore investigated the role of ASM in controlling caspase-
8 activation by cisplatin in H460 sh-BAXBAK clones. Pre-
treatment of cells with imipramine, a known inhibitor of ASM,
resulted in an attenuation of p18-caspase-8 generation
following treatment with cisplatin (Figure 5a). Similar results
were seen when ASM expression was silenced using siRNA,
as assessed by western blotting (Figure 5b). To establish
whether cisplatin-induced caspase-8 cleavage was ASM-
dependent, we studied this effect in other NSCLC cell lines.
In MOR and H1975 cells pretreated with imipramine, we
observed reduced p41/43-caspase-8 following cisplatin
treatment; p18-caspase-8 was not detectable in these cell
lines (Figure 5c). In addition, cisplatin-induced caspase-8
activity was suppressed with imipramine in H460 MOR and
H157 cells (Supplementary Figure S10) Ceramide clusters
were observed 24 h after cisplatin treatment in H460 cells,
but these were abolished following pre-treatment with
imipramine (Supplementary Figure S5). Together these data
confirm that ASM, responsible for ceramide generation
following cisplatin treatment, induces caspase-8 activation
in both parental and shBAX/BAK cell lines. Accordingly,
imipramine strongly attenuated caspase-3 activation follow-
ing cisplatin treatment in shBAX/BAK cells (Supplementary
Figure S6).
In cisplatin-resistant cells, caspase-8 can be activated
by TRAIL, but not by cisplatin. We have previously shown
that cisplatin-resistant cells harbour defective mitochondrial
signalling in response to cisplatin, owing to suppression of
BH3 death signals, whereas there is conservation of BAX/
BAK sensitivity to exogenous BH3 domains.32 We therefore
decided to investigate whether an analogous dysregulation of
the death receptor pathway signalling occurs in cisplatin-
resistant NSCLC. In both H460 cisplatin-resistant (CISPR)
cells developed in our laboratory (as described previously by
Crawford et al.32) and MOR CISPR cells,33 no caspase-8
cleavage was observed following cisplatin treatment,
although caspase-8 cleavage and apoptosis could be
efficiently induced by TRAIL (Figure 6a). Thus, the death
receptor apoptosis machinery is present in H460 CISPR and
MOR CISPR cells and remains functional in response to
receptor activation. Indeed, ceramide expression was shown
to increase in response to cisplatin in the H460 parental but
not the H460 cisplatin-resistant cells (Figure 6b). This was
Figure 3 Cisplatin induces caspase-8 cleavage in a panel of NSCLC cells but
not in H1299 cells. (a) Western blots showing processing of PARP and caspase-8 in
a panel of NSCLC cell lines with increasing doses of cisplatin for 24 h. (b) Western
blot for caspase-8 in H460 and H1299 sh-BAXBAK cells with matched sh-NTNT
controls after 24 h treatment with cisplatin (H460 15 mM, H1299 40mM)
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also observed in the MOR CISPR cells (not shown).
However, this block in ceramide generation was not due to
a block in ASM enzyme activity per se, as we detected no
difference in either basal, or cisplatin-induced ASM activity
between resistant and parental cells (Figure 6c). This
suggests that defective ASM is not responsible for failure
of caspase-8 cleavage in response to cisplatin in resistant
cells.
Figure 4 Caspase-8 mediates cisplatin-induced apoptosis in H460 sh-BAXBAK cells but not sh-NTNT control cells. (a) (i) Western blot showing siRNA-mediated silencing
of caspase-8 in H460 sh-BAXBAK clones. (ii) Flow cytometry of PI-stained H460 sh-BAXBAK clones, transfected for 48 h with caspase-8 siRNA (siC8) or scrambled control
(SC) and treated with cisplatin (5mM) or TRAIL (10 ng/ml) for 48 h. Apoptotic cells are indicated by increase in sub-G0/G1 population. Data are expressed as mean±S.D. (b)
(i) Western blot for caspase-8 and caspase-9 in H460 sh-NTNT cells after transfection for 48 h with C8 siRNA and treatment with cisplatin or TRAIL. Caspase-8 silencing
attenuates TRAIL induced but not cisplatin-induced caspase-9 cleavage. (ii) Flow cytometry of PI-stained H460 sh-NTNT cells, transfected for 48 h with caspase-8 siRNA
(siC8) or scrambled control (SC) and treated with cisplatin (15 mM) or TRAIL (10 ng/ml) for 48 h. Data are expressed as mean±S.D. (c) Western blots for PARP, caspase-8,
DR4, DR5, FADD. Caspase-8 and PARP cleavage, induced by cisplatin, is attenuated after siRNA-mediated silencing of DR4, DR5 and FADD in H460
sh-BAXBAK 1C
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Discussion
BAX and BAK are key regulators of the mitochondrial
apoptosis pathway as evidenced by knockout of BAX and
BAK in mouse embryonic fibroblasts.19 Their frequency of
loss in NSCLC prompted us to investigate whether functional
mitochondrial signalling was required for activity of cisplatin,
the most commonly used drug in the treatment of NSCLC. To
achieve this, we studied the effect of cisplatin in BAX/BAK-
silenced NSCLC cell lines and observed two different
phenotypes. In H460, caspase-8 cleavage was observed in
response to cisplatin, sufficient to induce apoptosis indepen-
dent of BAX and BAK. In contrast, H1299 cells showed no
evidence of caspase-8 cleavage in response to cisplatin and
so were unable to bypass mitochondrial apoptosis block
induced by loss of BAX and BAK. This is in agreement with
other reports showing that H1299 cells are resistant to ligand
stimulation of the death receptor pathway.30 Blocking death
receptor-mediated apoptosis, through depletion of caspase-8
by RNA interference, was sufficient to rescue H460 sh-
BAXBAK, but not sh-NTNT cells from cisplatin, demonstrating
redundancy between the two apoptotic pathways following
cisplatin treatment.
This is the first report to show that cisplatin can induce
apoptosis through a BAX/BAK-independent, ASM/caspase-8/
FADD-dependent fashion. This is contrary to our initial
hypothesis based on previous reports in BAX/BAK knockout
MEFs. Moreover, we found that sh-BAXBAK H460 cells were
more sensitive to cisplatin than parental cells. This could be
because of an impairment of mitochondrial network dynamics
and metabolism occurring after BAX/BAK depletion (for
review see Auret and Martin34), that could in turn lead to
increased sensitivity to toxic effect of the drug despite block of
caspase-9 activation following staurosporine. Although
bypass of the mitochondrial pathway was only observed in
the H460 sh-BAXBAK model, treatment of a panel of NSCLC
cell lines showed caspase-8 activation following cisplatin in
all, except H1299, suggesting that this is a potentially common
process in NSCLC. This is not surprising given our previous
report that procaspase-8 is overexpressed in 85% of NSCLC
compared with matched normal lung tissue.35
The finding that BAX and BAK are not essential for effective
apoptosis induction, led us to investigate the mechanism
regulating the mitochondrial bypass pathway and its potential
alteration in resistance to cisplatin. In both cell lines studied,
H460 and MOR, cisplatin-induced caspase-8 cleavage and
ceramide accumulation were abrogated in cisplatin-resistant
(CISPR) cells, but not in parental cells. However, the death
receptor pathway apparatus remained functional in both
cisplatin-resistant daughter cell lines, as evidenced by
caspase-8 cleavage, PARP cleavage and G0/G1 fraction
after treatment with rhTRAIL. This would suggest absence of
an upstream death signal initiating apoptosis via the death
receptor pathway. The importance of ceramide generation via
ASM for both cisplatin-induced apoptosis and death receptor-
dependent apoptosis has been demonstrated previously.36–38
Our data confirm generation of ceramide in response to
cisplatin in parental cells, but not in cisplatin-resistant cells
and this is not due to dysfunctional ASM in the resistant cells.
Although ASM has been shown to regulate cisplatin-induced
ceramide generation, production of ceramide requires aux-
iliary factors. It is possible that an as yet undefined functional
defect in one or more of these factors may explain lack of
cisplatin-induced ceramide generation in cisplatin-resistant
NSCLC cells. From a translational perspective, our data
suggest that in cisplatin-resistant cells, despite the absence of
ceramide generation and subsequent caspase-8 signalling in
response to cisplatin, DISC activation can still be achieved by
ligand stimulation of the death receptors with rhTRAIL.
In conclusion, cisplatin resistance requires a block in both
mitochondrial and a parallel, independent pathway involving
ASM/FADD/caspase-8. Importantly, selection for cisplatin
resistance leads to a block in death receptor apoptosis. These
cells, however, do not exhibit cross-resistance to death
receptor-targeted therapies such as TRAIL and silencing of
cFLIP (data not shown). These findings therefore support a
rationale for targeting the death receptor pathway, as a
strategy for bypassing platinum resistance.
Materials and Methods
Reagents, cytotoxics. Recombinant human TRAIL was purchased from
Calbiochem (Gibbstown, NJ, USA), Imipramine and staurosporine were purchased
from Sigma-Aldrich (St Louis, MO, USA); cisplatin was obtained from Mayne
Pharma, Adelaide, SA, Australia.
Cell culture. ATCC NCI-H1975, NCI-H460, NCI-H1299 and MOR non-small-
cell lung cancer (NSCLC) cells were grown in Roswell Park Memorial Institute
(RPMI) 1640 medium supplemented with 10% foetal bovine serum and 50 mg/ml
Figure 5 Cisplatin-induced caspase-8 cleavage is acid sphingomyelinase
(ASM)-dependent. (a) Western blot for caspase-8 after 2 h treatment with
imipramine (50mM) and 24 h cotreatment with cisplatin (5mM) in H460 sh-
BAXBAK cells. (b) Western blot for caspase-8 and ASM. (c) Western blot for
caspase-8 from MOR and H1975 treated as in (a) showing imipramine attenuates
cisplatin-induced caspase-8 cleavage in these NSCLC cell lines
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penicillin/streptomycin (Invitrogen, Paisley, UK). NCI-H157 NSCLC cells were
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% foetal
bovine serum, 1 mM sodium pyruvate and 50 mg/ml penicillin/streptomycin. All cell
lines were maintained in a 5% CO2 incubator at 37
oC.
Generation of BAX and BAK-silenced NSCLC cell lines. Plasmids
encoding shRNA sequences to BAX, BAK and NT shRNA (SA Biosciences,
Frederick, MD, USA) were transfected into H460 and H1299 NSCLC cells using
FuGene 6 reagent (Roche, Burgess Hill, West Sussex, UK) according to
Figure 6 Caspase-8 activation is blocked in cisplatin-resistant cells but can be activated by TRAIL. (a) (i) Western blot for PARP and caspase-8 in H460 and MOR paired
parental (Par) and cisplatin-resistant (CISPR) cells after 24 h cisplatin (15 mM) or TRAIL (10 ng/ml) treatment. (ii) Flow cytometry of PI-stained H460 and MOR paired parental
(Par) and cisplatin-resistant (CISPR) cells after 24 h cisplatin (15 mM) or TRAIL(10 ng/ml) treatment. Data are expressed as mean±S.D. (b) Representative images of cells
stained for ceramide (green) in H460 Par and CISPR cells. Cells were treated for 24 h with cisplatin (15 mM) or 4 h with TRAIL (10 ng/ml). (c) Fluorescent ASM activity assay
shows PAR and CISPR cells for H460 and MOR have equivalent baseline levels of ASM activity with a small increase after 24 h cisplatin treatment
Regulation of caspase-8 in cisplatin resistance
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manufacturer’s protocol. BAX plasmids with G418 resistance selection marker,
BAK plasmids with puromycin resistance selection marker and separate NT
plasmids bearing either G418 or puromycin resistance selection markers were
used. Cells were transfected cells in six-well plates and were incubated with either
G418 (H460–0.4 mg/ml, H1299–0.8 mg/ml) (Sigma-Aldrich) or 2mg/ml puromycin
(Calbiochem). Discrete colonies were selected and screened by western blotting.
Cells stably expressing shRNA targeting BAX were then re-transfected with shRNA
targeting BAK to generate clones with stable knockdown of both BAX and BAK.
siRNA transfections. The non-silencing control (SC) siRNA, caspase-8-
targeted (C8), FADD-targeted, DR5-targeted and DR4-targeted siRNA sequences
were the same as previously described.35,39 siRNAs for in vitro transfection were
obtained from Dharmacon (Chicago, IL, USA). SMARTpool ON-TARGET plus
ASM (SMPD1) siRNA was obtained from Dharmacon. Reverse siRNA
transfections were carried out using LipofectamineRNAi max reagent (Invitrogen)
according to the manufacturer’s instructions.
Western blotting. Twenty-five micrograms of cell lysate were loaded and
resolved by SDS-PAGE as previously described.40 Primary antibodies used were:
anti-caspase-8 (Alexis Biochemicals, San Diego, CA, USA), anti-PARP
(eBioscience, San Diego, CA, USA), anti-GAPDH (Serotec, Kidlington, UK),
anti-ASM, anti-a-tubulin (Abcam, Cambridge, MA, USA), anti-BAX, anti-BAK, anti
cleaved caspase-9 (Cell Signalling Technology Inc., Danvers, MA, USA) anti-DR4
(Calbiochem), anti-DR5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
FADD (BD Bioscience Oxford, Oxfordshire, UK). Secondary antibodies used were:
goat anti-mouse HRP (DAKO P0447, DAKO Ely, Cambridgeshire, UK) and goat
anti-rabbit HRP (DAKO P0448).
Caspase activity assay (8 and 3/7). For caspase activity assay, cells
were seeded at 5000/well in a white-walled 96-well plate 24 h before start of
experiment. Media was then replaced with drug concentrations as shown in the
text. Imipramine was added 2 h before cisplatin, where required. DEVD-ase
activity was determined after 24 h incubation with Caspase-glo luminescent assay
(Promega, Southampton, UK) according to manufacturer’s instructions, using a
Berthold luminometer with 1 s integration time.
Ceramide immunostaining. Cells were seeded onto a glass coverslip
inside a six-well plate at 150 000 cells per well, 24 h before start of experiment.
Cisplatin and/or imipramine were applied as described previously, and after 24 h
cells were fixed in 2% paraformaldehyde. Coverslips were incubated with anti-
ceramide antibody (Alexis) followed by goat anti-mouse AlexaFluor488 secondary
antibody (Invitrogen) and mounted on slides with Pro-long gold mountant with
DAPI (Invitrogen). Images were captured on a Leica DM microscope (Leica
Microsystems, Wetzlar, Germany) using a  40 objective lens.
Flow cytometry. Cells were seeded 48 h post transfection with siRNA as
described, at a density of 1 105 cells per well in six-well plates. Cells were
treated after 24 h and allowed to grow for a further 48 h. Following treatment with
cisplatin, DNA content was evaluated by propidium iodide staining of cells using a
FACS Calibur Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ, USA), in the
FL-2 channel to determine percentage of cells with DNA content o2N.
Surface expression of death receptors was assessed following live cell staining
with one of the phycoerythrin-conjugated monoclonal antibodies: DR4, DR5, Fas,
DcR2 (all from eBioscience) or TNFR1 antibody (R&D Systems, Minneapolis, MN,
USA). In all experiments, isotype control (mouse IgG1 from eBioscience) was used.
ASM activity assay. ASM activity was determined using an ASM activity
assay kit (Echelon Biosciences Inc., Salt Lake City, UT, USA) according to the
manufacturer’s protocol. Cells were disrupted using a microprobe sonicator
(Sonics Vibra-Cell VC 130 Ultrasonic Homogeniser) with 10 pulses (2 s on, 1 s off)
at 30% output. 30mg of protein was used to determine ASMase activity. Reaction
was stopped after incubation at 37 1C for 2 h and analysed using a fluorescence
plate reader at 260 nm excitation and 460 nm emission.
Statistical analysis. Statistical analyses were conducted using Microsoft
Office Excel 2007. Results were expressed as mean value±S.D. Differences
between groups were evaluated using unpaired two-tailed Student’s t-test.
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